Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Blood

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1182/blood-2013-01-478420PMID 24335499
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Genetic Architecture of Multiple Myeloma

  2014cited by this paper
• Addiction to c-MYC in multiple myeloma.

  2012cited by this paper
• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  2012cited by this paper
• Place your BETs: the therapeutic potential of bromodomains.

  2012cited by this paper
• BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.

  2012cited by this paper
• The genetic architecture of multiple myeloma

  2012cited by this paper
• Bromodomain and Extra-terminal (BET) Bromodomain Inhibition Activate Transcription via Transient Release of Positive Transcription Elongation Factor b (P-TEFb) from 7SK Small Nuclear Ribonucleoprotein*

  2012cited by this paper
• Targeting epigenetic readers in cancer.

  2012cited by this paper
• MYC addiction: a potential therapeutic target in MM.

  2012cited by this paper
• Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

  2011cited by this paper
• BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

  2011cited by this paper
• Pathogenesis of myeloma.

  2011cited by this paper
• Targeting MYC dependence in cancer by inhibiting BET bromodomains

  2011cited by this paper
• The genetic network controlling plasma cell differentiation.

  2011cited by this paper
• Clinical and Biological Implications of MYC Activation: A common difference between MGUS and newly diagnosed multiple myeloma

  2011cited by this paper
• Selective inhibition of BET bromodomains

  2010cited by this paper
• NUT midline carcinoma.

  2010cited by this paper
• Suppression of inflammation by a synthetic histone mimic

  2010cited by this paper
• c-Myc regulates transcriptional pause release.

  2010cited by this paper
• Acetylation of cyclin T1 regulates the equilibrium between active and inactive P‐TEFb in cells

  2009cited by this paper
• International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

  2009cited by this paper
• 7SK RNA, a non-coding RNA regulating P-TEFb, a general transcription factor

  2009cited by this paper
• Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.

  2008cited by this paper
• IRF4 addiction in multiple myeloma

  2008cited by this paper
• The multi-tasking P-TEFb complex.

  2008cited by this paper
• Chromatin modifications and their function.

  2007cited by this paper
• Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease.

  2007cited by this paper
• From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only.

  2007cited by this paper
• Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex

  2007cited by this paper
• Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease

  2007cited by this paper
• Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.

  2007cited by this paper
• HEXIM1 and the Control of Transcription Elongation: From Cancer and Inflammation to AIDS and Cardiac Hypertrophy

  2007cited by this paper
• The Double Bromodomain-containing Chromatin Adaptor Brd4 and Transcriptional Regulation*

  2007cited by this paper
• Modulation of a P-TEFb Functional Equilibrium for the Global Control of Cell Growth and Differentiation

  2006cited by this paper
• Molecular pathogenesis and a consequent classification of multiple myeloma.

  2005cited by this paper
• Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4.

  2005cited by this paper
• The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription.

  2005cited by this paper
• From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

  2005cited by this paper
• Focus on multiple myeloma.

  2004cited by this paper
• A comparison of normalization methods for high density oligonucleotide array data based on variance and bias

  2003cited by this paper
• NF-kappa B as a therapeutic target in multiple myeloma.

  2002cited by this paper
• NF-κB as a Therapeutic Target in Multiple Myeloma*

  2002cited by this paper
• NF-κB as a Therapeutic Target for Cardiovascular Disease

  2002cited by this paper
• Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.

  2001cited by this paper
• Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis.

  2001cited by this paper
• The transcriptional program of a human B cell line in response to Myc.

  2001cited by this paper
• Cancer genetics and cytogenetics

  1998cited by this paper
• Blood.

  1989cited by this paper
• Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

  1988cited by this paper
• Leukemia

  1984cited by this paper
• THE CANCER CELL

  1924cited by this paper
• Chromatin Modifications and Their Function

  year unknowncited by this paper

• Semi-rigid linkers improve the pharmacokinetic properties and therapeutic efficacy of BET PROTACs for cancer therapy.

  2026cites this paper
• Targeted degradation of BRD4 by PROTACs: advances in cancer therapy.

  2026cites this paper
• Recent Progress and Prospect in Studying Selective Inhibitors Toward Bromodomain Family Members

  2026cites this paper
• Multiple functions of BRD4 in maintaining genomic stability in cancers.

  2025cites this paper
• Design, synthesis, and antitumor evaluation of triazolopyridine derivatives as novel inhibitors for BRD4.

  2025cites this paper
• Epigenetic Dysregulation in Cancer: Implications for Gene Expression and DNA Repair-Associated Pathways

  2025cites this paper
• A First-in-Class Chemical-Induced Proximity System Achieves Dose-Dependent Control of Tumor Protein P53 Gene Activation in Preclinical Models of Gastric Cancer.

  2025cites this paper
• I-BET151 modulates glucokinase gene expression and beta cell function in part through changes in FOXO1 expression

  2025influential citation
• International guidelines on the diagnosis and treatment of NUT carcinoma.

  2025cites this paper
• A combinatorial screening protocol for identifying novel and highly potent dual-target inhibitor of BRD4 and STAT3 for kidney cancer therapy

  2025cites this paper
• Epigenetic Regulation and Therapeutic Targeting of Alternative Splicing Dysregulation in Cancer

  2025cites this paper
• A patent review of BRD4 inhibitors (2020–present)

  2025cites this paper
• PROTACs improve selectivity for targeted proteins

  2025cites this paper
• Targeting BRD4 in cancer therapy: From inhibitors and degraders to novel combination strategies and resistance mechanisms.

  2025cites this paper
• Comprehensive Characterization of HATs and HDACs in Human Cancers Reveals Their Role in Immune Checkpoint Blockade.

  2024cites this paper
• Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance.

  2024cites this paper
• Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors.

  2024cites this paper
• Exploring the landscape of post-translational modification in drug discovery.

  2024cites this paper
• Collaborative GSK-University of Strathclyde doctoral research and training programmes: Transforming approaches to industry-academia engagement.

  2024cites this paper
• Chromatin Remodeling-Related PRDM1 Increases Stomach Cancer Proliferation and Is Counteracted by Bromodomain Inhibitor

  2024cites this paper
• Unlocking the therapeutic potential of selective CDK7 and BRD4 inhibition against multiple myeloma cell growth

  2024cites this paper
• Marine natural product-inspired discovery of novel BRD4 inhibitors with anti-inflammatory activity.

  2024cites this paper
• BET degraders reveal BRD4 disruption of 7SK and P-TEFb is critical for effective reactivation of latent HIV in CD4+ T-cells

  2024cites this paper
• Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases.

  2023cites this paper
• An Update of Epigenetic Drugs for the Treatment of Cancers and Brain Diseases: A Comprehensive Review

  2023cites this paper
• Discovery of a potent, orally available tricyclic derivative as a novel BRD4 inhibitor for melanoma.

  2023cites this paper
• BRD4 promotes hepatic stellate cells activation and hepatic fibrosis via mediating P300/H3K27ac/PLK1 axis.

  2023cites this paper
• BET-HDAC Dual Inhibitors for Combinational Treatment of Breast Cancer and Concurrent Candidiasis.

  2023cites this paper
• Targeting epigenetic regulation for cancer therapy using small molecule inhibitors.

  2023cites this paper
• Domain-Selective BET Ligands Yield Next-Generation Synthetic Genome Readers/Regulators with Nonidentical Cellular Functions.

  2023cites this paper
• Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.

  2023cites this paper
• Epimutations and Their Effect on Chromatin Organization: Exciting Avenues for Cancer Treatment

  2022cites this paper
• Structure-Based Discovery and Optimization of Furo[3,2-c]pyridin-4(5H)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors.

  2022cites this paper
• Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML.

  2022cites this paper
• BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations

  2022cites this paper
• Transcription suppression is mediated by the HDAC1–Sin3 complex in Xenopus nucleoplasmic extract

  2022cites this paper
• Critical role for cap-independent c-myc translation in progression of multiple myeloma.

  2022cites this paper
• The paradigm of drug resistance in cancer: an epigenetic perspective

  2022cites this paper
• Cyclization strategy leads to highly potent Bromodomain and extra-terminal (BET) Bromodomain inhibitors for the treatment of acute liver injury.

  2022cites this paper
• A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

  2022influential citation
• Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases

  2022cites this paper
• Large-scale allosteric switch in the 7SK RNA regulates transcription in response to growth and stress

  2021cites this paper
• New Targeted Therapies for Multiple Myeloma Under Clinical Investigation

  2021cites this paper
• MYC Hyperactivates Wnt Signaling in APC/CTNNB1-Mutated Colorectal Cancer Cells through miR-92a–Dependent Repression of DKK3

  2021cites this paper
• Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors.

  2021cites this paper
• Gene Transcription as a Therapeutic Target in Leukemia

  2021cites this paper
• Computational repurposing of therapeutic small molecules from cancer to pulmonary hypertension

  2021cites this paper
• Identification of a Series of N-Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) Proteins.

  2021cites this paper
• Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit.

  2021cites this paper
• Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function

  2021cites this paper
• Chemogenomics for drug discovery: clinical molecules from open access chemical probes

  2021cites this paper
• Targeting epigenetic mechanisms to overcome venetoclax resistance.

  2021cites this paper
• Enhancer rewiring in tumors: an opportunity for therapeutic intervention

  2021cites this paper
• Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins

  2021cites this paper
• BRD4 methylation by the methyltransferase SETD6 regulates selective transcription to control mRNA translation

  2021cites this paper
• Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer

  2021cites this paper
• Achieving clinical success with BET inhibitors as anti-cancer agents

  2021cites this paper
• Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML)

  2021cites this paper
• Development of Dimethylisoxazole-Attached Imidazo[1,2-a]pyridines as Potent and Selective CBP/P300 Inhibitors.

  2021cites this paper
• Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors.

  2021cites this paper
• Hypertranscription and replication stress in cancer.

  2021cites this paper
• BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair

  2021cites this paper
• CRCM5484: A BET- BDII Selective Compound With Differential Anti-Leukemic Drug Modulation

  2021cites this paper
• The Role of lncRNAs in the Pathobiology and Clinical Behavior of Multiple Myeloma

  2021cites this paper
• Bromodomain‐containing protein 4 and its role in cardiovascular diseases

  2020cites this paper
• Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy

  2020cites this paper
• A review on kinases phosphorylating the carboxyl-terminal domain of RNA polymerase II-Biological functions and inhibitors.

  2020cites this paper
• The Optimisation of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor.

  2020cites this paper
• Brd/BET Proteins Influence the Genome-Wide Localization of the Kaposi’s Sarcoma-Associated Herpesvirus and Murine Gammaherpesvirus Major Latency Proteins

  2020cites this paper
• Modulating Epigenetic Modification Enzymes Through Relevant Epidrugs as a Timely Strategy in Anticancer Therapy

  2020cites this paper
• Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti‐tumor activity in multiple myeloma

  2020influential citation
• A 7-methoxybicoumarin derivative selectively inhibits BRD4 BD2 for anti-melanoma therapy.

  2020cites this paper
• Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer

  2020cites this paper
• Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins

  2020cites this paper
• BRD4 regulates self‐renewal ability and tumorigenicity of glioma‐initiating cells by enrichment in the Notch1 promoter region

  2020cites this paper
• Small Molecules Targeting the Specific Domains of Histone-Mark Readers in Cancer Therapy

  2020cites this paper
• BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs.

  2020cites this paper
• Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs

  2020cites this paper
• Approaching Complex Diseases: Network-Based Pharmacology and Systems Approach in Bio-Medicine

  2020influential citation
• Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease

  2020cites this paper
• Epigenetic Control Using Small Molecules in Cancer

  2020cites this paper
• Enhancing venetoclax activity in hematological malignancies

  2020cites this paper
• In Silico Guided Drug Repurposing to Combat SARS-CoV-2 by Targeting Mpro, the Key Virus Specific Protease

  2020cites this paper
• Epigenetic Drug Discovery for Cancer

  2019cites this paper
• Regulators of Histone Acetylation: Bromodomain Inhibitors

  2019cites this paper
• Combinatorial BRD4 and AURKA inhibition is synergistic against preclinical models of Ewing sarcoma

  2019cites this paper
• Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors

  2019cites this paper
• Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy

  2019cites this paper
• Emerging Epigenetic Targets and Their Implications in Cancer Therapy

  2019cites this paper
• SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors.

  2019cites this paper
• Bromodomain-Containing Protein 4: A Druggable Target.

  2019cites this paper
• Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

  2019cites this paper
• Epigenetics of Multiple Myeloma Bone Disease

  2019cites this paper
• Predicting response to BET inhibitors using computational modeling: A BEAT AML project study

  2019cites this paper
• Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.

  2019cites this paper
• BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity

  2019cites this paper
• Inhibition of BRD4 attenuates transverse aortic constriction- and TGF-β-induced endothelial-mesenchymal transition and cardiac fibrosis.

  2019cites this paper
• A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction

  2019cites this paper
• Regulatory mechanisms of B cell responses and the implication in B cell-related diseases

  2019cites this paper
• Pro-senescence therapy by targeting MYC and its network as a strategy to combat cancer

  2019cites this paper